For the year ending 2025-12-31, BCRX made $874,837K in revenue. $262,978K in net income. Net profit margin of 30.06%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenues | 874,837 | 450,712 | 331,412 | 270,827 |
| Cost of product sales | 19,075 | 12,269 | 4,481 | 6,408 |
| Research and development | 166,126 | 174,638 | 216,566 | 253,297 |
| Selling, general and administrative | 348,647 | 266,132 | 213,894 | 159,371 |
| Royalty | - | 216 | 180 | 186 |
| Total operating expenses | 533,848 | 453,255 | 435,121 | 419,262 |
| Income (loss) from operations | 340,989 | -2,543 | -103,709 | -148,435 |
| Interest income | 10,668 | 14,746 | - | - |
| Interest and other income | - | - | 15,777 | 5,127 |
| Interest expense | 78,872 | 98,516 | 108,239 | 99,092 |
| Foreign currency losses, net | -152 | -641 | -1,039 | -1,983 |
| Loss on extinguishment of debt | -17,332 | 0 | -29,019 | 0 |
| Other income | 12,090 | - | - | - |
| Total other expense, net | -73,598 | -84,411 | - | - |
| Income (loss) before income taxes | 267,391 | -86,954 | -226,229 | -244,383 |
| Income tax expense | 3,530 | 1,927 | 310 | 2,733 |
| Net income (loss) | 263,861 | -88,881 | -226,539 | -247,116 |
| Foreign currency translation adjustment | -674 | -776 | 180 | 890 |
| Unrealized (loss) gain on available for sale investments | -209 | 360 | - | - |
| Unrealized gain (loss) on available for sale investments | - | - | 1,131 | -1,041 |
| Total other comprehensive (loss) income | -883 | -416 | - | - |
| Net comprehensive income (loss) | 262,978 | -89,297 | -225,228 | -247,267 |
| Basic EPS | 1.26 | -0.43 | -1.18 | -1.33 |
| Diluted EPS | 1.21 | -0.43 | -1.18 | -1.33 |
| Basic Average Shares | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 |
| Diluted Average Shares | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)